A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain Metastases
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Opnurasib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms STRIDER
- 28 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Mar 2024 Planned initiation date changed from 1 Nov 2023 to 15 Apr 2024.
- 23 Aug 2023 New trial record